233 related articles for article (PubMed ID: 27071312)
1. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
Miura K; Takahashi H; Nakagawa M; Izu A; Sugitani M; Kurita D; Sakagami M; Ohtake S; Uchino Y; Hojo A; Kodaira H; Yagi M; Kobayashi Y; Iriyama N; Kobayashi S; Kiso S; Hirabayashi Y; Hatta Y; Takei M
Leuk Lymphoma; 2016; 57(6):1335-41. PubMed ID: 26390147
[TBL] [Abstract][Full Text] [Related]
3. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
4. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
[TBL] [Abstract][Full Text] [Related]
5. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
7. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
9. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
10. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.
Clark Schneider KM; Banks PM; Collie AM; Lanigan CP; Manilich E; Durkin LM; Hill BT; Hsi ED
Leuk Lymphoma; 2016 Jul; 57(7):1640-8. PubMed ID: 26421520
[TBL] [Abstract][Full Text] [Related]
11. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
12. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
14. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
[TBL] [Abstract][Full Text] [Related]
16. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
[TBL] [Abstract][Full Text] [Related]
17. Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Kawashima I; Inamoto Y; Maeshima AM; Nomoto J; Tajima K; Honda T; Shichijo T; Kawajiri A; Takemura T; Onishi A; Ito A; Tanaka T; Fuji S; Kurosawa S; Kim SW; Maruyama D; Tobinai K; Kobayashi Y; Fukuda T
Biol Blood Marrow Transplant; 2018 Feb; 24(2):294-300. PubMed ID: 29037890
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
20. Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma.
Chen H; Qin Y; Liu P; Yang J; Gui L; He X; Zhang C; Zhou S; Zhou L; Yang S; Shi Y
Mol Diagn Ther; 2023 Jan; 27(1):75-86. PubMed ID: 36401148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
